Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer


Study Number
41216
Phase
3
Purpose

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Full Title

(S1418/BR006) A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 [Pembrolizumab] as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After…

ClinicalTrials.Gov ID
NCT02954874

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.